TRITON2 Phase 2 trial

January 16, 2020January 16, 2020

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations. The priority review status ... Read more

October 24, 2018

Rubraca Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations

News

Rubraca (rucaparib), Clovis Oncology‘s PARP inhibitor, shrank tumors in 44% of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations included in a Phase 2 clinical trial, the company announced. ... Read more

February 7, 2017

Strata to Help Clovis Find Patients for Prostate Cancer Trials of Rucaparib

News

Strata Oncology will help Clovis Oncology accelerate patient enrollment in ongoing clinical trials assessing Clovis’ rucaparib as a treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA or ATM mutations. Strata is conducting ... Read more